Dose Optimization Study of Idelalisib in Follicular Lymphoma

NCT02536300 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
96
Enrollment
INDUSTRY
Sponsor class

Stopped Gilead has made the decision to close the study due to enrollment challenges

Conditions

Interventions

Sponsor

Gilead Sciences